Effects of tDCS on cognition in mild cognitive impairment
The Effects of Specific Transcranial Direct Current Stimulation tDCS on Cognition in Mild Cognitive Impairment: A Novel Study Protocol
This study is testing whether a brain stimulation technique called tDCS can improve thinking skills in people with mild cognitive impairment related to Alzheimer's and Parkinson's diseases.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 120 (estimated) |
| Ages | 45 Years to 80 Years |
| Sex | All |
| Sponsor | Istanbul Medipol University Hospital Academic / other |
| Locations | 1 site (Antalya, Alanya) |
| Trial ID | NCT05919485 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of transcranial direct current stimulation (tDCS) on cognitive skills in patients with mild cognitive impairment (MCI) related to Alzheimer's and Parkinson's diseases. The study involves a multicenter, randomized, controlled design where participants receive anodal tDCS applied to specific brain regions over 10 sessions within 14 days. Cognitive outcomes will be assessed using neurocognitive tests and brain connectivity will be analyzed through fMRI and EEG at various time points. The goal is to explore the potential cognitive benefits of tDCS and its implications for understanding MCI and Parkinson's disease.
Who should consider this trial
Good fit: Ideal candidates are literate individuals aged 45-80 diagnosed with Parkinson's disease-MCI or amnestic MCI.
Not a fit: Patients with existing neurological or psychiatric disorders, signs of dementia, or those unable to undergo fMRI or tDCS may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new non-invasive treatment options that help preserve cognitive function in patients with mild cognitive impairment.
How similar studies have performed: Other studies have shown promising results with tDCS in cognitive enhancement, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Providing an informed consent; 2. Literate and between 45-80 years of age; 3. 60 females and 60 males; 4. Diagnosed with PD based on criteria suggested by UK Parkinson's Disease Society, Brain Bank and PD-MCI in accordance with the diagnostic criteria suggestions by Litvan; 5. Diagnosed with aMCI based on diagnosis criteria (CDR\>0.5) suggested by Petersen; 6. On a stable pharmacological treatment minimum for one month with no washout period. Exclusion Criteria: * Illiterate or education level less than primary school * Having an existing and/or prior neurological disease; psychiatric disease or head trauma; and/or irreversible hearing or sight problems or other medical illness (e.g. diabetes mellitus, hypertension); * Exhibiting signs of dementia for PD group ; * Having medical issues that prevent undergoing fMRI or for tDCS application.
Where this trial is running
Antalya, Alanya
- Alanya Alaaddin Keykubat Üniversitesi — Antalya, Alanya, Turkey (Türkiye) (Recruiting)
Study contacts
- Study coordinator: Burak Yuluğ, Prof. DR. MD
- Email: burakyulug@gmail.com
- Phone: +90 242 510 6135
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.